Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma
Classical Hodgkin’s lymphoma is a highly curable disease, but 10–25% of patients with higher-risk disease relapse. The introduction of checkpoint inhibitors (CPIs) targeting PD-1 have changed the landscape of treatment for patients with relapsed/refractory disease to multiple lines of therapy. The d...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/12/2936 |
| _version_ | 1797489151858180096 |
|---|---|
| author | Shazia Nakhoda Farsha Rizwan Aldana Vistarop Reza Nejati |
| author_facet | Shazia Nakhoda Farsha Rizwan Aldana Vistarop Reza Nejati |
| author_sort | Shazia Nakhoda |
| collection | DOAJ |
| description | Classical Hodgkin’s lymphoma is a highly curable disease, but 10–25% of patients with higher-risk disease relapse. The introduction of checkpoint inhibitors (CPIs) targeting PD-1 have changed the landscape of treatment for patients with relapsed/refractory disease to multiple lines of therapy. The depth of response to CPI as a monotherapy is highest in the first relapse as salvage therapy based on outcomes reported in several phase II studies. With earlier use of CPI and brentuximab vedotin, the optimal sequencing of therapy is evolving. In this review, we will summarize clinical investigation of anti-PD-1 mAb in earlier line settings to provide insights on utilizing these agents as chemotherapy- and radiation-sparing approaches, increasing depth of response, and as part of combination regimens. |
| first_indexed | 2024-03-10T00:13:24Z |
| format | Article |
| id | doaj.art-c61ac1b9bbe34fcea44fb78bfa767363 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T00:13:24Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-c61ac1b9bbe34fcea44fb78bfa7673632023-11-23T15:56:41ZengMDPI AGCancers2072-66942022-06-011412293610.3390/cancers14122936Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s LymphomaShazia Nakhoda0Farsha Rizwan1Aldana Vistarop2Reza Nejati3Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USADepartment of Internal Medicine, Temple University Hospital, Philadelphia, PA 19140, USADepartment of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USADepartment of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USAClassical Hodgkin’s lymphoma is a highly curable disease, but 10–25% of patients with higher-risk disease relapse. The introduction of checkpoint inhibitors (CPIs) targeting PD-1 have changed the landscape of treatment for patients with relapsed/refractory disease to multiple lines of therapy. The depth of response to CPI as a monotherapy is highest in the first relapse as salvage therapy based on outcomes reported in several phase II studies. With earlier use of CPI and brentuximab vedotin, the optimal sequencing of therapy is evolving. In this review, we will summarize clinical investigation of anti-PD-1 mAb in earlier line settings to provide insights on utilizing these agents as chemotherapy- and radiation-sparing approaches, increasing depth of response, and as part of combination regimens.https://www.mdpi.com/2072-6694/14/12/2936checkpoint inhibitorsimmunotherapyHodgkin lymphoma |
| spellingShingle | Shazia Nakhoda Farsha Rizwan Aldana Vistarop Reza Nejati Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma Cancers checkpoint inhibitors immunotherapy Hodgkin lymphoma |
| title | Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma |
| title_full | Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma |
| title_fullStr | Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma |
| title_full_unstemmed | Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma |
| title_short | Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma |
| title_sort | updates in the role of checkpoint inhibitor immunotherapy in classical hodgkin s lymphoma |
| topic | checkpoint inhibitors immunotherapy Hodgkin lymphoma |
| url | https://www.mdpi.com/2072-6694/14/12/2936 |
| work_keys_str_mv | AT shazianakhoda updatesintheroleofcheckpointinhibitorimmunotherapyinclassicalhodgkinslymphoma AT farsharizwan updatesintheroleofcheckpointinhibitorimmunotherapyinclassicalhodgkinslymphoma AT aldanavistarop updatesintheroleofcheckpointinhibitorimmunotherapyinclassicalhodgkinslymphoma AT rezanejati updatesintheroleofcheckpointinhibitorimmunotherapyinclassicalhodgkinslymphoma |